EP0729361A4 - Procede de traitement de troubles neurologiques - Google Patents

Procede de traitement de troubles neurologiques

Info

Publication number
EP0729361A4
EP0729361A4 EP95901254A EP95901254A EP0729361A4 EP 0729361 A4 EP0729361 A4 EP 0729361A4 EP 95901254 A EP95901254 A EP 95901254A EP 95901254 A EP95901254 A EP 95901254A EP 0729361 A4 EP0729361 A4 EP 0729361A4
Authority
EP
European Patent Office
Prior art keywords
neurological disorders
treating neurological
treating
disorders
neurological
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP95901254A
Other languages
German (de)
English (en)
Other versions
EP0729361A1 (fr
Inventor
Christopher A Maack
Debra Brown
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Celtrix Pharmaceuticals Inc
Original Assignee
Celtrix Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Celtrix Pharmaceuticals Inc filed Critical Celtrix Pharmaceuticals Inc
Publication of EP0729361A1 publication Critical patent/EP0729361A1/fr
Publication of EP0729361A4 publication Critical patent/EP0729361A4/fr
Withdrawn legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/30—Insulin-like growth factors, i.e. somatomedins, e.g. IGF-1, IGF-2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Biomedical Technology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Zoology (AREA)
  • Epidemiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Hospice & Palliative Care (AREA)
  • Endocrinology (AREA)
  • Molecular Biology (AREA)
  • Diabetes (AREA)
  • Psychiatry (AREA)
  • Marine Sciences & Fisheries (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Steroid Compounds (AREA)
EP95901254A 1993-11-15 1994-11-15 Procede de traitement de troubles neurologiques Withdrawn EP0729361A4 (fr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US15286893A 1993-11-15 1993-11-15
US152868 1993-11-15
PCT/US1994/013177 WO1995013823A1 (fr) 1993-11-15 1994-11-15 Procede de traitement de troubles neurologiques

Publications (2)

Publication Number Publication Date
EP0729361A1 EP0729361A1 (fr) 1996-09-04
EP0729361A4 true EP0729361A4 (fr) 1996-11-06

Family

ID=22544799

Family Applications (1)

Application Number Title Priority Date Filing Date
EP95901254A Withdrawn EP0729361A4 (fr) 1993-11-15 1994-11-15 Procede de traitement de troubles neurologiques

Country Status (5)

Country Link
EP (1) EP0729361A4 (fr)
JP (1) JPH09509140A (fr)
AU (1) AU693489B2 (fr)
CA (1) CA2176708A1 (fr)
WO (1) WO1995013823A1 (fr)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6440928B1 (en) 1988-12-06 2002-08-27 Colorado State University Research Foundation Method for treating diabetic neuropathy with NGF
DE69627379T2 (de) * 1995-12-13 2004-02-05 Aurogen Inc., Fort Collins Igf-i and -ii zur behandlung von krankheiten im zentralnervensystem
US6025368A (en) * 1997-02-25 2000-02-15 Celtrix Pharmaceuticals, Inc. Method for treating the symptoms of chronic stress-related disorders using IGF
US6514937B1 (en) 1997-02-25 2003-02-04 Celtrix Pharmaceuticals, Inc. Method of treating psychological and metabolic disorders using IGF or IGF/IGFBP-3
US6015786A (en) * 1997-02-25 2000-01-18 Celtrix Pharmaceuticals, Inc. Method for increasing sex steroid levels using IGF or IGF/IGFBP-3
EP1006794B1 (fr) * 1997-03-12 2007-11-28 Robert W. Esmond Procede de traitement ou de prevention de la maladie d'alzheimer
US6436897B2 (en) * 1998-06-01 2002-08-20 Celtrix Pharmaceuticals, Inc. Pharmaceutical formulations for IGF/IGFBP
US6417330B1 (en) 1998-06-01 2002-07-09 Celtrix Pharmaceuticals, Inc. Insulin-like growth factor binding protein variants
US7288516B1 (en) 1999-09-20 2007-10-30 Celtrix Pharmaceuticals, Inc. Null IGF for the treatment of cancer
US6040292A (en) * 1999-06-04 2000-03-21 Celtrix Pharmaceuticals, Inc. Methods for treating diabetes
CA2422625A1 (fr) 2000-09-19 2002-03-28 Bioexpertise, Llc Utilisation de la proteine de liaison de l'igf pour la sensibilisation selective de cellules cibles in vivo
US7714020B2 (en) 2001-05-24 2010-05-11 Neuren Pharmaceuticals Limited Treatment of non-convulsive seizures in brain injury using G-2-methyl-prolyl glutamate
US7605177B2 (en) 2001-05-24 2009-10-20 Neuren Pharmaceuticals Limited Effects of glycyl-2 methyl prolyl glutamate on neurodegeneration
JP2004536069A (ja) 2001-05-24 2004-12-02 ニューロンズ・リミテッド Ｇｐｅ類縁体及びペプチドミメティック
CA2460719A1 (fr) 2001-09-18 2003-03-27 Bioexpertise, Llc Peptide ou petite molecule derive de proteines de liaison de l'igf
US6914049B2 (en) 2001-09-18 2005-07-05 Bioexpertise, Llc IGF-binding protein-derived peptide or small molecule
US6887851B2 (en) 2001-09-18 2005-05-03 Bioexpertise, Llc IGF-binding protein-derived peptide
US20040142359A1 (en) * 2002-11-14 2004-07-22 Wyeth Methods and compositions for treating neurological disorders
US7833513B2 (en) 2004-12-03 2010-11-16 Rhode Island Hospital Treatment of Alzheimer's Disease
RU2669692C1 (ru) * 2017-08-14 2018-10-15 Павел Андреевич Канаев Способ получения комплекса биологически активных пептидов обладающих нейротропной активностью
WO2023242442A1 (fr) * 2022-06-17 2023-12-21 Oak Hill Bio Limited Procédé de maturation/différenciation de neurones et/ou de modulation du nerf vague

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0227619A2 (fr) * 1985-12-13 1987-07-01 KabiGen AB Protéine et son application
WO1993008826A1 (fr) * 1991-11-08 1993-05-13 Cephalon, Inc. Traitement des troubles neuronaux retiniens par application de facteurs de croissance semblables a l'insuline et des analogues de ceux-ci
WO1993020836A1 (fr) * 1992-04-15 1993-10-28 Cephalon, Inc. Traitement de maladies au moyen de facteurs de croissance semblables a l'insuline (igf) et d'analogues
WO1993025219A1 (fr) * 1992-06-12 1993-12-23 Cephalon, Inc. Prevention et traitement de la neuropathie peripherique

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE8703625D0 (sv) * 1987-09-18 1987-09-18 Kabivitrum Ab New medical use
US5258287A (en) * 1988-03-22 1993-11-02 Genentech, Inc. DNA encoding and methods of production of insulin-like growth factor binding protein BP53
US5093317A (en) * 1989-06-05 1992-03-03 Cephalon, Inc. Treating disorders by application of insulin-like growth factor
US5187151A (en) * 1991-02-12 1993-02-16 Genentech, Inc. Use of binding protein with igf-i as an anabolic growth promoting agent
SE9101341D0 (sv) * 1991-05-03 1991-05-03 Kabi Pharmacia Ab New medicinal use
DK0597033T3 (da) * 1991-08-01 1997-06-02 Genentech Inc IGF-1 til forbedring af den neurale tilstand

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0227619A2 (fr) * 1985-12-13 1987-07-01 KabiGen AB Protéine et son application
WO1993008826A1 (fr) * 1991-11-08 1993-05-13 Cephalon, Inc. Traitement des troubles neuronaux retiniens par application de facteurs de croissance semblables a l'insuline et des analogues de ceux-ci
WO1993020836A1 (fr) * 1992-04-15 1993-10-28 Cephalon, Inc. Traitement de maladies au moyen de facteurs de croissance semblables a l'insuline (igf) et d'analogues
WO1993025219A1 (fr) * 1992-06-12 1993-12-23 Cephalon, Inc. Prevention et traitement de la neuropathie peripherique

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
LEWIS ET AL: "THE POTENTIAL OF INSULIN-LIKE GROWTH FACTOR-I AS A THERAPEUTIC FOR THE TREATMENT OF NEUROMUSCULAR DISORDERS", ANNALS OF THE NEW YORK ACADEMY OF SCIENCES,USA, vol. 692, 1993, MEETING OF NOVEMBER,1992,ARLINGTON,VIRGINIA,USA, pages 201 - 208, XP002012439 *
See also references of WO9513823A1 *

Also Published As

Publication number Publication date
JPH09509140A (ja) 1997-09-16
AU1057095A (en) 1995-06-06
AU693489B2 (en) 1998-07-02
CA2176708A1 (fr) 1995-05-26
WO1995013823A1 (fr) 1995-05-26
EP0729361A1 (fr) 1996-09-04

Similar Documents

Publication Publication Date Title
EP0729361A4 (fr) Procede de traitement de troubles neurologiques
EP0771203A4 (fr) Procede de traitement de pathologies associees a la transpiration
AUPM864894A0 (en) Treatment of bowel-dependent neurological disorders
AU4918796A (en) Methods of treating or preventing psychiatric disorders
EP0820467A4 (fr) Procedes de traitement de troubles oculaires
PL350961A1 (en) Method of treating neurological and neuropsychiatric disorders
EP0493037A3 (en) Method of treating thromboembolic disorders
ZA952372B (en) Method of treating fine ore
ZA947751B (en) Method of treating septic shock using thymosin-alpha 1
GB9218027D0 (en) Novel method of treatment
EP0866716A4 (fr) Procedes de traitement de troubles dans des epitheliums sensoriels non visuels
EP0732938A4 (fr) Procede pour traiter des troubles intestinaux
GB9202196D0 (en) Method of treatment
GB9507825D0 (en) Method of treatment
GB2294880B (en) Method of treating turf
GB9415902D0 (en) Method of treatment
GB9201391D0 (en) Method of treatment
GB9324568D0 (en) Treatment of neurological and psychiatric disorders
GB9407335D0 (en) Method of treatment
HK1044900A1 (zh) 用於治療神經病或神經精神疾病的方法
GB9218597D0 (en) Novel method of treatment
GB9513034D0 (en) Treatment of neurological and psychiatric disorders
GB9413556D0 (en) The treatment of neurological and psychiatric disorders
GB9307004D0 (en) Method of treatment
GB9321796D0 (en) Method of treatment

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 19960607

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AT BE CH DE DK ES FR GB GR IE IT LI LU MC NL PT SE

A4 Supplementary search report drawn up and despatched

Effective date: 19960916

AK Designated contracting states

Kind code of ref document: A4

Designated state(s): AT BE CH DE DK ES FR GB GR IE IT LI LU MC NL PT SE

RIN1 Information on inventor provided before grant (corrected)

Inventor name: BROWN, DEBRA

Inventor name: MAACK, CHRISTOPHER A.

17Q First examination report despatched

Effective date: 20000613

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN

18D Application deemed to be withdrawn

Effective date: 20001214